Sle Clinical Trials 2024

Sle Clinical Trials 2024

Sle research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in sle clinical trials today.

Sle Clinical Trials

Here are the 6 most popular medical studies for sle

Popular filter options for sle trials

Obstructive Sleep Apnea Clinical Trials

View 18 Obstructive Sleep Apnea medical studies.

Type 1 Diabetes Clinical Trials

View 14 Type 1 Diabetes medical studies.

Charlottesville, Virginia

Cell Therapy

Pancreatic Islets of Langerhans Cell Transplant for Type 1 Diabetes

Recruiting1 awardPhase 1
Charlottesville, Virginia

This protocol will provide islet cell transplantation to two separate populations in need of a pancreas transplant: Group I: Islet Cell Transplantation in Type I Diabetics without Kidney Problems Group II: Islet Cell Transplantation in Type I Diabetics Who Have a Stable Functioning Kidney Transplant The targeted patients have very brittle diabetes or dangerous hypoglycemic unawareness and may benefit from transplantation over continuing insulin therapy, even though chronic immunosuppression is required. We believe that in these patients, the islet transplant procedure promises enough potential benefit to justify subjecting patients who have not previously had a transplant to the risk of immunosuppression. In patients who are already subject to the dangers of chronic immunosuppression for other reasons, i.e. to prevent rejection of a kidney allograft, the islet transplantation procedure itself is the principal additional risk and this risk should be minimal. In these patients (our Group II), the potential benefit from improved glycemic control is that it promises to slow or even reverse diabetic complications, such as vascular problems leading to kidney damage. It is this rationale that has made pancreas transplantation a widely accepted option in patients with renal failure, despite the risks associated with whole pancreas transplantation. Islet cell transplantation aims to provide a potentially lower risk procedure that has similar relief from diabetic complications.

Phase 3 Sle Clinical Trials

View 82 phase 3 sle medical studies.

Sle Clinical Trials With No Placebo

View 82 sle medical studies that do not have a placebo group.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to sle

What are the top hospitals conducting sle research?

When it comes to advancing the understanding and treatment of Systemic Lupus Erythematosus (SLE), several top hospitals are leading the way with their clinical trials. In Nashville, Vanderbilt University Medical Center is making strides with five ongoing SLE trials and a total of six completed trials since they began their first recorded trial in 2017. Moving north to Chicago, Northwestern University has been actively involved in this research field as well, currently conducting four active SLE trials alongside an impressive history of 14 completed studies dating back to their inaugural trial in 2002.

Meanwhile, the renowned Mayo Clinic located in Rochester also plays a significant role by contributing valuable insights through its four ongoing SLE trials and involvement in five prior investigations spanning from as early as 1995. Washington University School of Medicine situated in Saint Louis demonstrates dedication towards addressing SLE through three current clinical trials while adding depth to this commitment with six previous studies conducted since initiating their initial trial back in 2013.

Adding itself to this list is NYU Langone Health based out of New york City where researchers are currently engaging with three active clinical tests focusing on SLE; interestingly theirs marks a new era being traced back only two years ago from2023 when they first launched their pioneering investigation into these cases.

These hospitals serve as vital contributors toward fighting against systemic lupus erythematosus, a complex autoimmune condition that affects multiple organs and systems within the body. Through cutting-edge research and innovative clinical trials conducted at these institutions across different locations, patients affected by SLE can find hope for improved treatments and ultimately better quality of life. Their collective efforts symbolize progress toward unraveling the mysteries surrounding this challenging disease

Which are the best cities for sle clinical trials?

When it comes to clinical trials for systemic lupus erythematosus (SLE), several cities in the United States are at the forefront of research. New york, with its 20 active trials, explores treatments such as Hydroxychloroquine (HCQ) and Administration of CC-97540 among others. Following closely behind is Houston, Texas, with 19 ongoing studies focusing on interventions like Cenerimod 4 mg and ALPN-101. Chicago, Illinois also plays a significant role in SLE research with 14 active trials investigating treatments including Dupilumab and BIIB059 High Dose. These cities provide valuable opportunities for individuals seeking participation in cutting-edge SLE clinical trials that may lead to improved treatment options and better outcomes.

Which are the top treatments for sle being explored in clinical trials?

In the realm of systemic lupus erythematosus (SLE) clinical trials, one treatment has emerged as a frontrunner: Cenerimod 4 mg. This cutting-edge drug is currently being explored in two active SLE trials and marks its debut in 2018 with only one all-time SLE trial to date. With ongoing research and development, Cenerimod holds great promise for revolutionizing the treatment landscape for SLE patients worldwide.

What are the most recent clinical trials for sle?

Recent clinical trials offer hope for individuals living with systemic lupus erythematosus (SLE), as innovative treatments and interventions are being explored. One notable trial is investigating the effectiveness of dupilumab, a medication that shows promise in managing SLE symptoms. Additionally, another study focuses on the administration of CC-97540, aiming to identify its potential benefits in treating this complex autoimmune disease. Furthermore, a Phase 2 trial referred to as Group 1 aims to evaluate an experimental intervention specifically designed for SLE patients. Another promising avenue lies in cenerimod 4 mg, which is undergoing Phase 3 testing for its efficacy against SLE symptoms. Lastly, researchers are exploring the impact of health communication messages on improving outcomes for individuals with SLE through a combined Phase 1 and Phase 2 study. With these diverse investigations underway, advancements towards better management and treatment options for SLE appear within reach.

What sle clinical trials were recently completed?

Recently, several clinical trials investigating potential treatments for systemic lupus erythematosus (SLE) have been successfully completed. Notably, in February 2022, Daiichi Sankyo concluded a trial studying DS-7011a's effectiveness. Earlier, Viela Bio's trial on VIB7734 was finalized in June 2021 while Sanofi wrapped up their SAR443122 trial in April 2021. Eli Lilly and Company also completed a study on LY3471851 back in August 2020. These trials represent significant strides towards finding better therapies for SLE patients and highlight the ongoing commitment of various pharmaceutical companies to tackle this challenging autoimmune disease head-on.